VerifiedRx Podcast Por Vizient Center for Pharmacy Practice Excellence arte de portada

VerifiedRx

VerifiedRx

De: Vizient Center for Pharmacy Practice Excellence
Escúchala gratis

Delivering short doses of insight for hospitals’ frontline pharmacy professionals, the Vizient pharmacy team brings together experts to verify best practices for navigating today’s pharmacy practice challenges and accelerating career growth. It’s a prescription for success, delivered by the Vizient Center for Pharmacy Practice Excellence.Copyright 2025 All rights reserved. Ciencia Economía Enfermedades Físicas Gestión Gestión y Liderazgo Higiene y Vida Saludable
Episodios
  • Healthcare Without Walls: The Growth of Consumer - Driven Care

    Healthcare Without Walls: The Growth of Consumer - Driven Care
    May 26 2026

    Direct-to-consumer healthcare is changing how patients engage with care, driven by growing demand for convenience, accessibility, and personalized experiences. VerifiedRx host Stacy Lauderdale is joined by Emily Fitt, Hailey Mulliner, and Heather Pace to discuss the continued rise of telehealth and direct-to-consumer healthcare platforms, the areas experiencing the most growth, and what these evolving models may mean for patients, providers, and health systems in the future.

    Guest Speakers: Emily Fitt, MHA, MPH Senior Associate, Sg2 Intelligence Vizient, Inc.

    Hailey Mulliner, MS-HSM Senior Director, Sg2 Intelligence Vizient, Inc.

    Heather Pace, Pharm.D. Senior Clinical Manager, Ambulatory Vizient, Inc.

    Host: Stacy Lauderdale, Pharm.D., BCPS AVP, Evidence-Based Medicine Vizient

    Show Notes:

    (00:52) The panel discusses where direct-to-consumer healthcare has gained the most traction, including:

    • Men’s reproductive health
    • Women’s contraceptives
    • Dermatology and acne care
    • Behavioral health
    • GLP-1 and obesity management

    (01:59) Heather explains how GLP-1 medication shortages fueled growth in compounded obesity medications and expanded telehealth services.

    (02:47) Hailey shares insights from SG2 consumer surveys, emphasizing how patients increasingly want customizable, convenient healthcare experiences like other consumer industries.

    (03:26) The group explores future expansion areas for direct-to-consumer healthcare, including:

    • Cardiovascular disease management
    • Type 2 diabetes
    • Orthopedic care
    • Cardiometabolic disease monitoring

    (04:31) Discussion shifts to the benefits and drawbacks for patients, including:

    • Increased convenience and access
    • More comfortable treatment environments
    • Greater patient empowerment
    • Risks of fragmented care and disconnected treatment plans

    (06:07) Emily outlines concerns for health systems, including:

    • Increased emergency department utilization
    • Lack of coordinated care
    • Medication management gaps
    • Challenges identifying medications prescribed outside the health system

    (07:03) Heather discusses medication stewardship concerns, particularly as weight loss impacts management of other chronic conditions like hypertension.

    (07:29) The panel highlights operational challenges for hospitals and procedural teams when patients fail to disclose GLP-1 medications prior to surgeries or colonoscopies.

    (07:58) The conversation turns to how direct-to-consumer healthcare is permanently changing consumer expectations around convenience and accessibility.

    (08:36) The panel debates whether health systems should compete with direct-to-consumer companies or pursue partnership strategies.

    (09:51) Emily discusses how health systems can differentiate themselves by offering the full continuum of care that virtual only providers cannot.

    (10:20) Heather Pace emphasizes the importance of partnerships between health systems and direct-to-consumer platforms to improve access while maintaining coordinated care.

    (10:55) The group discusses emerging partnerships in the marketplace, including collaborations between pharmaceutical manufacturers and direct-to-consumer platforms.

    (12:14)Workforce challenges are explored, including:

    • Competition for clinicians
    • Provider burnout
    • Flexibility offered by virtual care employers

    (13:17) The panel examines future trends involving AI, including patients using AI to interpret labs and emerging AI-assisted prescribing models in behavioral health.

    (14:24) Closing thoughts on how direct-to-consumer healthcare is reshaping patient expectations and forcing health systems to rethink care delivery models.

    Subscribe Today!

    Apple Podcasts

    Spotify

    YouTube

    RSS Feed

    Más Menos
    15 m
  • Beyond Revenue: Measuring Specialty Pharmacy Team Value

    Beyond Revenue: Measuring Specialty Pharmacy Team Value
    May 12 2026

    Defining and documenting pharmacist interventions beyond prescription revenue is essential to demonstrating the full value of pharmacy teams. Host Carolyn Liptak is joined by Dr. Karen Thomas from the University of Illinois Chicago and Dr. Thom Platt from UK Healthcare to share insights from a multi-system survey exploring how interventions are captured and used. They discuss the variability in current practices, the important role of both pharmacists and technicians, and the opportunity to better quantify clinical and operational impact to C-suite.

    Guests:

    Karen C. Thomas, PharmD, PhD, MBA Associate Director, Specialty and Infusion Pharmacies University of Illinois Hospital and Health System

    Thom Platt, PharmD, PhD, MBA ,BCPS Director of Specialty Pharmacy Services UK HealthCare

    Host: 

    Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance Vizient Center for Pharmacy Practice Excellence

    Show Notes:

    00:05 – Introduction Overview of VerifiedRx and the focus on pharmacy practice excellence.

    00:14 – Episode Overview & Guest Introductions Host Carolyn Liptak introduces the topic: capturing the value of pharmacist interventions beyond prescription revenue. Guests:

    • Dr. Karen Thomas, University of Illinois Chicago
    • Dr. Thom Platt, UK Healthcare

    00:57 – Health System Backgrounds

    • UIC serves a diverse urban population with a strong Medicaid and Medicare presence
    • UK Healthcare supports patients across Kentucky and surrounding states, including rural populations traveling long distances for specialty care

    01:48 – What Sparked the Research

    • Originated from a Vizient work group focused on outcomes and value
    • Need for clearer frameworks to document and report pharmacist interventions
    • Lack of standardized guidance from accrediting bodies and payers

    02:56 – Survey Goals and Key Findings

    • Explored how health systems define and document interventions
    • Identified major variability in data collection and reporting
    • Found alignment in defining clinical interventions, less consistency in non clinical ones
    • Included responses from 24 health systems

    04:21 – Broader Impact on Pharmacy Practice

    • Reinforces the value of pharmacist contributions beyond revenue
    • Highlights prevention of hospital visits and improved patient outcomes
    • Emphasizes the need to better capture and communicate this value

    05:38 – Applying the Research in Practice

    • UIC developed a structured framework and documentation tool
    • Supports initiatives like waste avoidance studies
    • Aims to quantify cost savings from pharmacist interventions

    06:49 – Relevance Beyond Specialty Pharmacy

    • Concepts apply across all pharmacy settings
    • Data can support staffing, funding, and program expansion decisions
    • Helps communicate value to internal and external stakeholders

    07:52 – Role of Pharmacy Technicians

    • 96 percent of sites report technician involvement in non clinical interventions
    • Examples include resolving medication access issues and addressing social barriers
    • Technicians play a critical role in patient support and care coordination

    09:58 – Future Opportunities

    • Push toward standardizing intervention data collection
    • Opportunity to reduce duplication of effort across health systems
    • Goal to create scalable, shared frameworks

    10:41 – Strategic Value of Intervention Data

    • Supports conversations with leadership and external partners
    • Demonstrates impact on outcomes like reduced ED visits and length of stay
    • Strengthens partnerships with payers and manufacturers

    11:34 – Additional Resources

    • Study published in the Online Journal of Pharmacy
    • Link available for listeners to explore further

    12:03 – Closing Remarks Final thoughts and appreciation for guests Call to action: subscribe, share feedback, and stay engaged with VerifiedRx

    Links and Resources: https://www.mdpi.com/2226-4787/13/6/172

    Subscribe Today!

    Apple Podcasts

    Spotify

    YouTube

    RSS Feed

    Más Menos
    13 m
  • Alpha-gal Syndrome and Impact on Patient Safety

    Alpha-gal Syndrome and Impact on Patient Safety
    Apr 28 2026
    Alpha-gal syndrome is an emerging and often underrecognized allergy triggered by a tick bite that can cause delayed reactions to red meat and mammalian-derived products. In this episode, host Stacy Lauderdale is joined by clinical experts Zack Stacy and Kyna Henrici to unpack the science behind alpha-gal, its implications in healthcare settings, and the operational challenges providers face in managing this complex condition. Guest Speakers: Zachary Stacy, Pharm.D., MS, FCCP, BCPS Clinical Pharmacy Specialist, Surgery BJC Health Kyna Henrici, RN Medical Evidence Director - Cardiovascular Vizient, Inc. Host: Stacy Lauderdale, Pharm.D., BCPS AVP, Evidence-Based Medicine Vizient, Inc. 00:05 – Introduction Podcast introduction and welcome to VerifiedRx 00:14 – What is alpha-gal syndrome Overview of alpha-gal syndrome Delayed allergic reactions after eating red meat Often linked to tick bites 00:48 – Meet the Guests Zack Stacy, clinical pharmacy specialist Kyna Henrici, medical evidence director 01:10 – Understanding the Allergy Alpha-gal is a carbohydrate in nonprimate mammals that can trigger an allergy in humans Key difference is delayed reaction timing Symptoms are not always easy to trace 01:32 – How It Develops Triggered by tick bites Immune system produces IgE antibodies Oral exposure to alpha-gal leads to delayed reactions IV exposure to alpha-gal can cause immediate reactions 02:17 – Prevalence and Diagnosis Challenges More common in Midwest and southern United States Likely underdiagnosed Often mistaken for general food allergies Allergy may fade over time 03:07 – Risks in Healthcare Settings Patient safety concerns beyond food Mammalian components in medications and devices Examples include heparin and surgical materials 03:44 – Hidden Medication Risks Inactive ingredients can be animal derived Examples include glycerin, lactose, amino acids, stearates Difficult to identify and track 04:42 – Lack of Transparency No centralized ingredient database Sourcing can change frequently Variability across manufacturers and batches 05:33 – Screening in Surgical Settings Medication review at NDC level Identification of active and inactive ingredients May require contacting manufacturers 06:45 – Timing Challenges Urgent procedures limit investigation time Manufacturer responses may take days Alternative medications often needed 07:14 – Identifying At Risk Patients Many patients are unaware they have alpha-gal syndrome Screening includes questions about dairy tolerance Three patient categories used for evaluation 08:32 – Using Dairy as a Screening Tool Dairy tolerance helps guide risk level Food exposure typically higher than medication exposure Determines need for deeper review 09:12 – Managing Emergencies Focus shifts from avoidance to risk mitigation Use of team communication and clear documentation Preparation for unavoidable exposure 10:03 – Prevention and Preparedness Stock alpha-gal safe medications when possible Prepare for allergic reactions with standard treatments 10:47 – Team Based Care Approach Collaboration across care teams is essential Premedication strategies may be used Close monitoring for reactions 11:11 – Gaps in Care Limited visibility into product ingredients Need for better labeling and transparency 11:33 – Need for Standardization Call for clearer guidance and clinician education Desire for centralized resource for medication ingredients 12:24 – Monitoring Challenges CDC tracking decreased after privatization of testing Cases likely still increasing 12:53 – Closing Remarks Links and Resources: Alpha-gal Syndrome | Alpha-gal Syndrome | CDC Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
    Más Menos
    14 m
adbl_web_anon_alc_button_suppression_c
Todavía no hay opiniones